For U.S. Media Only

Boehringer Ingelheim Earns Top Marks in 2010 Corporate Equality Index

Once again, Boehringer Ingelheim earns 100 percent in Human Rights Campaign Foundation’s Eighth Annual Index

Ridgefield, CT, September 15, 2009 — Boehringer Ingelheim proudly announced that it has earned the top rating of 100 percent in the 2010 Corporate Equality Index (CEI), an annual survey administered by the Human Rights Campaign Foundation. Boehringer Ingelheim joins the ranks of 305 other major U.S. businesses which get top marks for their treatment of lesbian, gay, bisexual and transgender (LGBT) employees and consumers.

“We are proud to receive this recognition once again.  We are committed to maintaining an inclusive environment where all of our employees feel respected,” said J. Martin Carroll, Boehringer Ingelheim President and CEO. “We will continue to look for ways to improve our current programs and introduce innovative new ones.”

The CEI rated 590 business in total, evaluating LGBT-related policies and practices including non-discrimination policies, transgender health benefits and domestic partner benefits. Boehringer Ingelheim’s efforts in ensuring LGBT equality in each of the survey’s main criterion earned it the prestigious 100 percent ranking.

About CEI
The CEI rated 590 businesses in total, evaluating LGBT-related policies and practices including non-discrimination policies, transgender health benefits and domestic partner benefits.

The Corporate Equality Index 2010 report is available at www.hrc.org/cei.

Boehringer Ingelheim Pharmaceuticals, Inc.
Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 138 affiliates in 47 countries and approximately 41,300 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2008, Boehringer Ingelheim posted net sales of US $17 billion (11.6 billion euro) while spending approximately one-fifth of net sales in its largest business segment, Prescription Medicines, on research and development.

For more information, please visit http://us.boehringer-ingelheim.com.

 

© 2009-2010 Boehringer Ingelheim Corporation or an affiliated company. All rights reserved. Use of this site is subject to the terms and conditions set out in the Agreement to use the Boehringer Ingelheim Corporation and its U.S. affiliates' web sites. All content intended for U.S. residents only. Terms of Use and Privacy Policy.